We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson Q3 Preview: Can the Earnings Streak Continue?
Read MoreHide Full Article
The Zacks Medical Sector has primarily traded in line with the S&P 500 in 2022, down roughly 22%.
A titan in the sector, Johnson & Johnson (JNJ - Free Report) , is on deck to unveil quarterly results on October 18th before the market open.
Headquartered in New Jersey, Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Currently, the company carries a Zacks Rank #3 (Hold) with an overall VGM Score of a C.
How does everything else shape up for the pharmaceutical titan heading into its quarterly print? Let’s take a closer look.
Share Performance & Valuation
Year-to-date, JNJ shares have displayed remarkable relative strength, down just 2% and easily crushing the general market’s performance.
Image Source: Zacks Investment Research
However, over the last three months, the story has been a bit different; JNJ shares have declined 7%, underperforming the S&P 500 by a fair margin.
Image Source: Zacks Investment Research
Further, JNJ shares trade at respectable levels, further bolstered by its Style Score of a B for Value.
The company’s 16.4X forward earnings multiple sits just a tick below its 16.8X five-year median, reflecting a 22% discount relative to its Zacks Sector.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish for the quarter to be reported, with three downwards estimate revisions hitting the tape over the last several months. The Zacks Consensus EPS Estimate of $2.51 pencils in a nearly 4% drop in quarterly earnings Y/Y.
Image Source: Zacks Investment Research
However, the company’s top-line is in better shape; the Zacks Consensus Sales Estimate of $23.5 billion suggests a marginal 0.7% year-over-year uptick.
Quarterly Performance & Market Reactions
JNJ has a stellar earnings track record, exceeding the Zacks Consensus EPS Estimate in each quarter dating all the way back to 2012. Just in its latest print, the company penciled in a slight 0.8% EPS beat.
Top-line results have left some to be desired as of late, with Johnson & Johnson exceeding revenue estimates just once across its last four prints. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
For those that like to trade around the company’s earnings releases, it’s worth noting that JNJ shares have moved upwards following five of its last six quarterly reports.
Putting Everything Together
JNJ shares have been remarkably defensive in 2022 but have lagged behind the general market over the last several months.
Valuation multiples don’t appear stretched, with the company’s forward earnings multiple sitting just below its five-year median and nowhere near its Zacks Sector average.
Analysts have been bearish in their earnings outlook, and estimates reflect a decline in earnings but an uptick in revenue – likely a reflection of margin compression.
JNJ has consistently exceeded bottom-line estimates throughout its history, but top-line results have left some to be desired over its last four prints.
Heading into the quarterly print, Johnson & Johnson (JNJ - Free Report) carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 1.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson Q3 Preview: Can the Earnings Streak Continue?
The Zacks Medical Sector has primarily traded in line with the S&P 500 in 2022, down roughly 22%.
A titan in the sector, Johnson & Johnson (JNJ - Free Report) , is on deck to unveil quarterly results on October 18th before the market open.
Headquartered in New Jersey, Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Currently, the company carries a Zacks Rank #3 (Hold) with an overall VGM Score of a C.
How does everything else shape up for the pharmaceutical titan heading into its quarterly print? Let’s take a closer look.
Share Performance & Valuation
Year-to-date, JNJ shares have displayed remarkable relative strength, down just 2% and easily crushing the general market’s performance.
Image Source: Zacks Investment Research
However, over the last three months, the story has been a bit different; JNJ shares have declined 7%, underperforming the S&P 500 by a fair margin.
Image Source: Zacks Investment Research
Further, JNJ shares trade at respectable levels, further bolstered by its Style Score of a B for Value.
The company’s 16.4X forward earnings multiple sits just a tick below its 16.8X five-year median, reflecting a 22% discount relative to its Zacks Sector.
Image Source: Zacks Investment Research
Quarterly Estimates
Analysts have been bearish for the quarter to be reported, with three downwards estimate revisions hitting the tape over the last several months. The Zacks Consensus EPS Estimate of $2.51 pencils in a nearly 4% drop in quarterly earnings Y/Y.
Image Source: Zacks Investment Research
However, the company’s top-line is in better shape; the Zacks Consensus Sales Estimate of $23.5 billion suggests a marginal 0.7% year-over-year uptick.
Quarterly Performance & Market Reactions
JNJ has a stellar earnings track record, exceeding the Zacks Consensus EPS Estimate in each quarter dating all the way back to 2012. Just in its latest print, the company penciled in a slight 0.8% EPS beat.
Top-line results have left some to be desired as of late, with Johnson & Johnson exceeding revenue estimates just once across its last four prints. Below is a chart illustrating the company’s revenue on a quarterly basis.
Image Source: Zacks Investment Research
For those that like to trade around the company’s earnings releases, it’s worth noting that JNJ shares have moved upwards following five of its last six quarterly reports.
Putting Everything Together
JNJ shares have been remarkably defensive in 2022 but have lagged behind the general market over the last several months.
Valuation multiples don’t appear stretched, with the company’s forward earnings multiple sitting just below its five-year median and nowhere near its Zacks Sector average.
Analysts have been bearish in their earnings outlook, and estimates reflect a decline in earnings but an uptick in revenue – likely a reflection of margin compression.
JNJ has consistently exceeded bottom-line estimates throughout its history, but top-line results have left some to be desired over its last four prints.
Heading into the quarterly print, Johnson & Johnson (JNJ - Free Report) carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 1.3%.